CTMA (CTMA)

CTMA (CTMA) is a company listed on the BATS.

As of Oct 23, 2026: returns 1 week -0.3%.

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company that pioneered the development of engineered macrophage and monocyte cell therapies. Its proprietary platform focuses on Chimeric Antigen Receptor Macrophages (CAR-M) to treat solid tumors, liver fibrosis, and autoimmune diseases.

CTMA financial model: income statement, cash flow and balance sheet